A Multicenter Phase 1A/1B Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2018
Price : $35 *
At a glance
- Drugs Altiratinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Deciphera Pharmaceuticals
- 30 Jan 2018 Status changed from active, no longer recruiting to discontinued.
- 13 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Jul 2016 Planned number of patients changed from 48 to 105.